A method for synthesizing a key intermediate of nemofloxacin
By optimizing the four-step reaction process of key Nanofloxacin intermediates, the problems of reaction product complexity and purification difficulties were solved, and the synthesis of high purity and high yield was achieved, and the operation process was simplified.
Patent Information
- Application Number
- CN202411175658.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-26
AI Technical Summary
The complexity of reaction products in the synthesis route of existing nanerofloxacin key intermediates is difficult to follow-up purification, resulting in low purity and low yield.
Using a four-step reaction process, the reaction and purification of compounds are carried out using different solvents and reagents, including the first reaction of compound 1 and the condensing agent, the third reaction of compound 2 and reagent 3, and the compound 3 and reagent 5 and reagent The fifth reaction of 6, the sixth reaction of compound 4 and reagent 7, improves purity and yield by optimizing reaction conditions and solvent selection.
The high purity (up to 99.5%) and high yield (up to 85%) of the target product were achieved, simplifying the operation process and avoiding recrystallization steps.
Smart Images

Figure CN118666744B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of organic synthesis, and in particular to a method for synthesizing a key intermediate of nemofloxacin. Background Art
[0002] Fluoroquinolone antibiotics have the advantages of broad antibacterial spectrum, strong antibacterial activity, low adverse reactions, good tissue permeability, high oral bioavailability and convenient dosing interval. They are commonly used antibiotics for the treatment of infectious diseases such as respiratory tract infections and urinary tract infections. The structural characteristics of fluoroquinolone antibiotics are that they all contain fluorine at the 6th position of the quinolone mother nucleus. However, in the past 10 years, due to the selective pressure generated by the widespread use of this type of drugs, the number of drug-resistant strains has increased. In particular, the quinolone-resistant Streptococcus pneumoniae that has emerged in recent years has cross-resistance and is resistant to penicillin, macrolide antibiotics and quinolone antibiotics. At the same time, it has been found that some fluoroquinolone antibiotics can cause adverse reactions such as prolonged OTC interval of electrocardiogram, liver toxicity and phototoxicity. In order to overcome the above shortcomings of fluoroquinolone antibiotics, it is urgent to develop new quinolone structural compounds with good antibacterial activity against multidrug-resistant bacteria, a broad antibacterial spectrum and as few adverse reactions as possible. In this context, nemofloxacin came into being, and the synthesis research of its key intermediate 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid is also underway.
[0003] The structural formula of 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid is: .
[0004] The synthetic routes of the intermediate - 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid reported in the patents are mainly as follows:
[0005] Synthesis route 1: Patent CN101045695 reported a synthesis method using 2,4-difluoroacetophenone as the starting material, such as Figure 1 As shown. This route uses compound 1 as the starting material, and obtains the target compound through carbonyl protection, aromatic ring hydroxylation, hydroxymethylation, condensation, substitution, cyclization, and hydrolysis. The starting material (compound 1) is currently in small supply on the market, and its stable supply has a greater risk. At the same time, dangerous reagents such as butyl lithium and sodium hydride are used in the reaction process.
[0006] Synthesis route 2: The synthesis route reported in patent CN103819401, such as Figure 2 This route uses compound I as the starting material, and obtains the target compound X through substitution, aromatic ring hydroxylation, hydroxymethylation, acylation, condensation, substitution, cyclization, and hydrolysis.
[0007] After comprehensive comparison, the inventor tried the second synthetic route, using compound V as the starting material, first reacting with thionyl chloride to form compound VI, and then reacting with N,N -Dimethylamino ethyl acrylate is reacted to obtain compound VII, which is then reacted with cyclopropylamine to obtain compound VIII, and finally cyclized and hydrolyzed to obtain the target compound X. After a large number of experiments, the inventors found that although the second step reaction (compound VI→compound VII) can obtain the target compound, the reaction is complicated and subsequent purification is difficult. The purity of the target compound X is generally low and the yield is low. Summary of the invention
[0008] In order to solve the above problems, the present invention provides a method for synthesizing a key intermediate of nemofloxacin.
[0009] The present invention provides a method for synthesizing a key intermediate of nemofloxacin, wherein the key intermediate of nemofloxacin is 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid, and the method comprises the following steps:
[0010] Compound 1 and a condensing agent are added to solvent 1 for a first reaction, and then reagent 1 is added for a second reaction to obtain compound 2;
[0011] The compound 2 is subjected to a third reaction with reagent 2 and reagent 3, and then solvent 2 and reagent 4 are added to conduct a fourth reaction to obtain compound 3;
[0012] Adding the compound 3, the reagent 5 and the reagent 6 into the solvent 3 to carry out a fifth reaction to obtain the compound 4;
[0013] The compound 4 and the reagent 7 are added to the solvent 4 to carry out the sixth reaction, and then the reagent 8 is added to carry out the seventh reaction to obtain the key intermediate of nemofloxacin;
[0014] The structural formula of the compound 1 is: ; The structural formula of the reagent 1 is: ; The structural formula of the compound 2 is: ; The reagent 2 is one of trimethyl orthoformate and triethyl orthoformate; the reagent 3 is one of acetic anhydride, propionic anhydride and butyric anhydride; the reagent 4 is cyclopropylamine; the structural formula of the compound 3 is: ; The reagent 5 is one of potassium carbonate, sodium hydroxide, potassium hydroxide, DIPEA, TEA, and DBU; the reagent 6 is one of sodium chloride, potassium chloride, lithium chloride, and magnesium chloride; the structural formula of the compound 4 is: ; The reagent 7 is one of potassium carbonate, sodium hydroxide, potassium hydroxide, and lithium hydroxide; the reagent 8 is one of hydrochloric acid, sulfuric acid, and phosphoric acid.
[0015] Furthermore, the mass ratio of the compound 1 to the solvent 1 is 1:3-20; the molar ratio of the compound 1 to the reagent 1 is 1:1.2-3.0; the molar ratio of the compound 1 to the condensing agent is 1:1.0-2.0;
[0016] The solvent 1 includes dichloromethane, dichloroethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran, acetonitrile, ethyl acetate, isopropyl acetate, dimethyl sulfoxide, 1,4-dioxane, N , N -dimethylformamide, N -methyl pyrrolidone; the condensing agent is one of HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridine-3-oxide hexafluorophosphate), HBTU (O-(benzotriazole-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate), HCTU (6-chloro-1-hydroxybenzotriazole-1-yl-oxytris(dimethylamino)phosphine hexafluorophosphate), CDI (carbonyldiimidazole), and EDCI (1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride);
[0017] The condition parameters of the first reaction and the second reaction are: temperature of 10-40° C. and time of 0.5-10 hours.
[0018] Furthermore, the mass ratio of the compound 1 to the solvent 1 is 1:5-10; the molar ratio of the compound 1 to the reagent 1 is 1:1.5-2.5; the molar ratio of the compound 1 to the condensing agent is 1:1.1-1.2;
[0019] The solvent 1 is ethyl acetate; the condensing agent is CDI;
[0020] The condition parameters of the first reaction and the second reaction are: temperature of 20-30° C. and time of 0.5-10 hours.
[0021] Further, the mass ratio of the compound 2 to the solvent 2 is 1:3-20; the molar ratio of the compound 2 to the reagent 2 is 1:1.0-2.0; the molar ratio of the compound 2 to the reagent 3 is 1:1.1-3.0; the molar ratio of the compound 2 to the reagent 4 is 1:1.0-2.0;
[0022] The solvent 2 includes dichloromethane, dichloroethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran, acetonitrile, methanol, anhydrous ethanol, ethyl acetate, isopropyl acetate, dimethyl sulfoxide, 1,4-dioxane, N , N -dimethylformamide, N-methyl pyrrolidone; the reagent 2 is triethyl orthoformate; the reagent 3 is acetic anhydride;
[0023] The condition parameters of the third reaction include: temperature of 80-120° C., and time of 1-10 hours; the condition parameters of the fourth reaction include: temperature of 0-50° C., and time of 1-10 hours.
[0024] Further, the mass ratio of the compound 2 to the solvent 2 is 1:5-10; the molar ratio of the compound 2 to the reagent 2 is 1:1.1-1.2; the molar ratio of the compound 2 to the reagent 3 is 1:1.5-2.0; the molar ratio of the compound 2 to the reagent 4 is 1:1.2-1.5;
[0025] The solvent 2 is anhydrous ethanol;
[0026] The condition parameters of the third reaction include: temperature of 90-110° C., and time of 3-5 hours; the condition parameters of the fourth reaction include: temperature of 20-30° C., and time of 4-6 hours.
[0027] Furthermore, the mass ratio of the compound 3 to the solvent 3 is 1:3-20; the molar ratio of the compound 3 to the reagent 5 is 1:1.0-2.0; the molar ratio of the compound 3 to the reagent 6 is 1:1.1-3.0;
[0028] The solvent 3 includes dichloromethane, dichloroethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran, acetonitrile, methanol, anhydrous ethanol, ethyl acetate, isopropyl acetate, dimethyl sulfoxide, 1,4-dioxane, N , N -dimethylformamide, N - at least one of methyl pyrrolidone; the reagent 5 is DIPEA; the reagent 6 is potassium chloride;
[0029] The condition parameters of the fifth reaction include: temperature of 0-80° C. and time of 1-10 hours.
[0030] Furthermore, the mass ratio of the compound 3 to the solvent 3 is 1:5-10; the molar ratio of the compound 3 to the reagent 5 is 1:1.1-1.2; the molar ratio of the compound 3 to the reagent 6 is 1:2.0-2.5;
[0031] The solvent 3 is anhydrous ethanol;
[0032] The condition parameters of the fifth reaction include: temperature of 60-80° C. and time of 3-6 hours.
[0033] Furthermore, the mass ratio of the compound 4 to the solvent 4 is 1:3-20; the molar ratio of the compound 4 to the reagent 7 is 1:1.0-2.0;
[0034] The solvent 4 includes water, tetrahydrofuran, 2-methyltetrahydrofuran, acetonitrile, methanol, anhydrous ethanol, dimethyl sulfoxide, 1,4-dioxane, N , N -dimethylformamide, N - at least one of methyl pyrrolidone; the reagent 7 is sodium hydroxide; the reagent 8 is hydrochloric acid;
[0035] The condition parameters of the sixth reaction include: temperature of 0-100° C. and time of 1-10 hours.
[0036] Furthermore, the condition parameters of the sixth reaction include: temperature of 20-40° C. and time of 2-4 hours.
[0037] The above technical solution provided by the embodiment of the present invention has at least the following advantages compared with the prior art:
[0038] The embodiment of the present invention provides a method for synthesizing a key intermediate of nemofloxacin, and the present invention adopts a completely innovative method for synthesizing 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid. The problem that the reaction product in route 2 is relatively mixed and difficult to purify subsequently is solved. In addition, each step of the present invention is easy to operate, the total yield of the four steps is high (up to about 85%), and no special recrystallization step is required. The purity of the obtained target product can reach more than 99.5%. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the invention and, together with the description, serve to explain the principles of the invention.
[0040] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.
[0041] Figure 1 The present invention is a flow chart of a first synthetic route of 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid in the prior art.
[0042] Figure 2 The present invention is a flow chart of the second synthetic route of 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid in the prior art.
[0043] Figure 3 The synthetic route of 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid provided in the embodiment of the present invention.
[0044] Figure 4 This is the H NMR spectrum of 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid obtained in Example 1 of the present invention.
[0045] Figure 5 This is the mass spectrum of 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid obtained in Example 1 of the present invention.
[0046] Figure 6 This is a liquid chromatogram of 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid obtained in Example 1 of the present invention. DETAILED DESCRIPTION
[0047] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0048] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.
[0049] The present invention provides a method for synthesizing a key intermediate of nemofloxacin, wherein the key intermediate of nemofloxacin is 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid. Figure 3 As shown, the method comprises the following steps:
[0050] Step 1:
[0051]
[0052] The compound 2,4-difluoro-3-methoxybenzoic acid of formula 1 is used as a raw material, and is first reacted with a condensation agent in a solvent 1 to generate an active ester, and then reagent 1 is added to react to generate compound 2.
[0053] In step 1, the solvent 1 is dichloromethane, dichloroethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran, acetonitrile, ethyl acetate, isopropyl acetate, dimethyl sulfoxide, 1,4-dioxane, N , N -dimethylformamide, N -Methyl pyrrolidone, etc.; preferably ethyl acetate.
[0054] In step 1, the mass ratio of compound 1 to solvent 1 is 1:3-20; preferably 1:5-10.
[0055] In step 1, the condensing agent is one of HATU, HBTU, HCTU, CDI and EDCI; preferably CDI.
[0056] In step 1, the molar ratio of compound 1 to the condensing agent is 1:1.0-2.0; preferably 1:1.1-1.2.
[0057] In step 1, the reagent 1 is potassium salt of monoethyl malonate.
[0058] In step 1, the molar ratio of compound 1 to reagent 1 is 1:1.2-3.0; preferably 1:1.5-2.5.
[0059] In step 1, the reaction temperature is 10-40°C, preferably 20-30°C.
[0060] In step 1, the reaction time is 1 to 10 hours, preferably 4 to 6 hours.
[0061] Step 2:
[0062]
[0063] The compound of formula 2 is used as a raw material, first reacts with reagent 2 and reagent 3 to generate an intermediate state, then solvent 2 is added after concentration, and finally reacts with reagent 4 to generate compound 3.
[0064] In step 2, the solvent 2 is dichloromethane, dichloroethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran, acetonitrile, methanol, anhydrous ethanol, ethyl acetate, isopropyl acetate, dimethyl sulfoxide, 1,4-dioxane, N , N -dimethylformamide, N -Methyl pyrrolidone, etc.; preferably anhydrous ethanol.
[0065] In step 2, the mass ratio of compound 2 to solvent 2 is 1:3-20; preferably 1:5-10.
[0066] In step 2, the reagent 2 is one of trimethyl orthoformate and triethyl orthoformate; preferably triethyl orthoformate.
[0067] In step 2, the molar ratio of compound 2 to reagent 2 is 1:1.0-2.0; preferably 1:1.1-1.2.
[0068] In step 2, the reagent 3 is one of acetic anhydride, propionic anhydride and butyric anhydride; preferably acetic anhydride.
[0069] In step 2, the molar ratio of compound 2 to reagent 3 is 1:1.1-3.0; preferably 1:1.5-2.0.
[0070] In step 2, the reagent 4 is cyclopropylamine.
[0071] In step 2, the molar ratio of compound 2 to reagent 4 is 1:1.0-2.0; preferably 1:1.2-1.5.
[0072] In step 2, the reaction temperature with reagent 2 and reagent 3 is 80-120°C, preferably 90-110°C.
[0073] In step 2, the reaction time with reagent 2 and reagent 3 is 1 to 10 hours, preferably 3 to 5 hours.
[0074] In step 2, the reaction temperature with reagent 4 is 0-50°C, preferably 20-30°C.
[0075] In step 2, the reaction time with reagent 4 is 1 to 10 hours, preferably 4 to 6 hours.
[0076] Step 3:
[0077]
[0078] The compound of formula 3 is used as a raw material, and reacts with reagents 5 and 6 in solvent 3 to generate compound 4.
[0079] In step 3, the solvent 3 is dichloromethane, dichloroethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran, acetonitrile, methanol, anhydrous ethanol, ethyl acetate, isopropyl acetate, dimethyl sulfoxide, 1,4-dioxane, N , N -dimethylformamide, N -Methyl pyrrolidone, etc.; preferably anhydrous ethanol.
[0080] In step 3, the mass ratio of compound 3 to solvent 3 is 1:3-20; preferably 1:5-10.
[0081] In step 3, the reagent 5 is one of potassium carbonate, sodium hydroxide, potassium hydroxide, DIPEA, TEA, and DBU; preferably DIPEA.
[0082] In step 3, the molar ratio of compound 3 to reagent 5 is 1:1.0-2.0; preferably 1:1.1-1.2.
[0083] In step 3, the reagent 6 is one of sodium chloride, potassium chloride, lithium chloride and magnesium chloride; preferably potassium chloride.
[0084] In step 3, the molar ratio of compound 3 to reagent 6 is 1:1.1-3.0; preferably 1:2.0-2.5.
[0085] In step 3, the reaction temperature is 0-80°C, preferably 60-80°C.
[0086] In step 3, the reaction time is 1 to 10 hours, preferably 3 to 6 hours.
[0087] Step 4:
[0088]
[0089] The compound of formula 4 is used as a raw material, and reacts with a reagent 7 in a solvent 4 to generate a salt of a compound 5, which is then acidified to obtain a compound 5 (i.e., the target product).
[0090] In step 4, the solvent 4 is water, tetrahydrofuran, 2-methyltetrahydrofuran, acetonitrile, methanol, anhydrous ethanol, dimethyl sulfoxide, 1,4-dioxane, N , N -dimethylformamide, N -Methylpyrrolidone, etc.; preferably water.
[0091] In step 4, the mass ratio of compound 4 to solvent 4 is 1:3-20; preferably 1:8-15.
[0092] In step 4, the reagent 7 is one of potassium carbonate, sodium hydroxide, potassium hydroxide, and lithium hydroxide; preferably sodium hydroxide.
[0093] In step 4, the molar ratio of compound 4 to reagent 7 is 1:1.0-2.0; preferably 1:1.5-2.0.
[0094] In step 4, the reagent 8 is one of hydrochloric acid, sulfuric acid and phosphoric acid; preferably hydrochloric acid.
[0095] In step 4, the reaction temperature is 0-100°C, preferably 20-40°C.
[0096] In step 4, the reaction time is 1 to 10 hours, preferably 2 to 4 hours.
[0097] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are usually measured in accordance with national standards. If there are no corresponding national standards, the general international standards, conventional conditions, or the conditions recommended by the manufacturer are followed; the raw materials involved are directly commercially available products unless otherwise specified.
[0098] Example 1
[0099] This example provides a method for synthesizing a key intermediate of nemofloxacin, wherein the key intermediate of nemofloxacin is 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid, and the method comprises the following steps:
[0100] 1) Preparation of intermediate compound 2
[0101]
[0102] Reaction: 160 ml of ethyl acetate, 20.0 g of compound 1 (106.3 mmol) and 48.4 g of HCTU (116.9 mmol, 1.1 equivalent) were added to the reaction flask in sequence, and the mixture was stirred at 25°C for 0.5 hour. 27.1 g of potassium monoethyl malonate (159.5 mmol, 1.5 equivalent) was added, and the mixture was stirred at 25°C for 5 hours.
[0103] Post-treatment: 18% hydrochloric acid was added to the reaction solution to adjust the pH to below 2, and stirring was continued for 1 hour. The liquids were separated, the aqueous phase was discarded, and the obtained organic phase was washed with 80 ml*2 water. The organic phase was concentrated under reduced pressure at 50°C to obtain the intermediate compound 2 (26.7 g, yield 97.2%).
[0104] 2) Preparation of intermediate compound 3
[0105]
[0106] Reaction: 20.0g of compound 2 (77.5mmol), 13.8g of triethyl orthoformate (93.1mmol, 1.2eq) and 14.2g of acetic anhydride (139.1mmol, 1.8 equivalents) were added to the reaction flask in sequence, and stirred at 100°C for 4 hours. After the reaction was completed, the volatiles were evaporated under reduced pressure at the reaction temperature. When no fraction was evaporated, the temperature was lowered to 25°C in a water bath, 200ml of anhydrous ethanol was added, and 5.8g of cyclopropylamine (101.6mmol, 1.3 equivalents) was added dropwise, and the temperature was controlled at 25°C and stirred for 5 hours.
[0107] Post-treatment: The reaction solution was cooled to 5°C, 600 ml of water was added dropwise, and the mixture was stirred and crystallized at 0-10°C for 2 h. The mixture was filtered and washed once with 20 ml of water. The wet product was dried under vacuum at 50°C for 12 h to obtain intermediate compound 3 (24.0 g, yield 95.2%).
[0108] 3) Preparation of intermediate compound 4
[0109]
[0110] Reaction: 180 ml of anhydrous ethanol, 20.0 g of compound 3 (61.5 mmol), 9.5 g of DIPEA (73.5 mmol, 1.2 eq) and 10.1 g of potassium chloride (135.5 mmol, 2.2 eq) were added to a reaction flask in sequence and stirred at 70°C for 5 hours.
[0111] Post-treatment: The reaction solution was cooled to 25°C, 600 ml of water was added dropwise, and the mixture was stirred and crystallized at 25°C for 2 h. The mixture was filtered and washed once with 20 ml of anhydrous ethanol. The wet product was dried in vacuo at 60°C for 10 h to obtain intermediate compound 4 (17.9 g, yield 95.4%).
[0112] 4) Preparation of Compound 5, a key intermediate of nemofloxacin
[0113]
[0114] Reaction: Add 150 ml of water and 3.3 g of sodium hydroxide (82.5 mmol, 1.7 equivalents) to the reaction flask in sequence, stir until completely dissolved, add 15.0 g of compound 4 (49.1 mmol), and stir at 30°C for 3 hours.
[0115] Post-treatment: under ice-water bath, add 18% hydrochloric acid dropwise to adjust pH to 3, maintain stirring at 20°C for crystallization for 1 hour, filter, wash once with 30 ml water, and dry the wet product under vacuum at 60°C for 15 hours to obtain the key intermediate of nemofloxacin - compound 5 (13.1 g, yield 96.2%).
[0116] The characterization spectrum of compound 5, the key intermediate of nemofloxacin obtained in this example, is as follows Figure 4 , Figure 5 and Figure 6 As shown; among them, the hydrogen spectrum analysis data is as follows: 1 HNMR (400 MHz, DMSO- d 6 )δ14.76(s, 1H), 8.75(s, 1H), 8.14(dd, J =9.1, 6.0Hz, 1H), 7.63(dd, J=10.6, 9.1Hz, 1H), 4.22(tt, J =7.0, 4.2Hz, 1H), 4.02(d, J =1.6Hz, 3H), 1.25–1.10 (m, 3H).
[0117] Example 2
[0118] In this example, based on Example 1, a single factor variable method (i.e., only one parameter condition in Example 1 was adjusted, and the remaining steps and conditions were the same as in Example 1) was used to conduct a screening test on the reaction condition parameters in the preparation steps of the intermediate compound 2. The specific parameter conditions of each single variable and the yield of the intermediate compound 2 obtained are shown in Table 1.
[0119] Table 1 Screening test and results of each reaction condition parameter in the preparation steps of intermediate compound 2
[0120]
[0121] Example 3
[0122] In this example, based on Example 1, a single factor variable method (i.e., only one parameter condition in Example 1 was adjusted, and the remaining steps and conditions were the same as in Example 1) was used to conduct a screening test on the reaction condition parameters in the preparation of the intermediate compound 3. The specific parameter conditions of each single variable and the yield of the intermediate compound 3 obtained are shown in Table 2.
[0123] Table 2 Screening test and results of each reaction condition parameter in the preparation steps of intermediate compound 3
[0124]
[0125]
[0126] Example 4
[0127] In this example, based on Example 1, a single factor variable method (i.e., only one parameter condition in Example 1 was adjusted, and the remaining steps and conditions were the same as in Example 1) was used to conduct a screening test on the reaction condition parameters in the preparation of the intermediate compound 4. The specific parameter conditions of each single variable and the yield of the intermediate compound 4 obtained are shown in Table 3.
[0128] Table 3 Screening test and results of each reaction condition parameter in the preparation steps of intermediate compound 4
[0129]
[0130] Example 5
[0131] In this example, based on Example 1, a single factor variable method (i.e., only one parameter condition in Example 1 was adjusted, and the remaining steps and conditions were the same as in Example 1) was used to screen the reaction condition parameters in the preparation of the key intermediate of nemonoxacin - compound 5. The specific parameter conditions of each single variable and the yield of the obtained target compound 5 are shown in Table 4.
[0132] Table 4 Screening test and results of each reaction condition parameter in the preparation steps of target compound 5
[0133]
[0134] In summary, the embodiment of the present invention provides a method for synthesizing a key intermediate of nemofloxacin, and the present invention adopts a completely innovative method for synthesizing 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid. The problem that the reaction product in route 2 is relatively complex and difficult to purify subsequently is solved. In addition, each step of the present invention is simple to operate, the total yield of the four steps is high (up to about 85%), and no special recrystallization step is required, and the purity of the obtained target product can reach more than 99.5%.
[0135] Various embodiments of the present invention may be presented in the form of a range; it should be understood that the description in the form of a range is only for convenience and brevity, and should not be understood as a rigid limitation on the scope of the present invention; therefore, the range description should be considered to have specifically disclosed all possible sub-ranges and single numerical values within the range. For example, the range description from 1 to 6 should be considered to have specifically disclosed sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as single numbers within the range, such as 1, 2, 3, 4, 5 and 6, which apply regardless of the range. In addition, whenever a numerical range is indicated herein, it is meant to include any cited number (fractional or integer) within the indicated range.
[0136] The foregoing is merely a specific embodiment of the present invention, which enables those skilled in the art to understand or implement the present invention. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features claimed herein.
Claims
1. A method for synthesizing a key intermediate of nemofloxacin, characterized in that: The key intermediate of nemofloxacin is 1-cyclopropyl-4-oxo-7-fluoro-8-methoxy-1,4-dihydroquinoline-3-carboxylic acid, and the synthesis method comprises the following steps: 1) Preparation of intermediate compound of formula 2 Reaction: 160 ml of ethyl acetate, 20.0 g of the compound of formula 1 and 48.4 g of HCTU were added to the reaction flask in sequence, stirred at 25°C for 0.5 hour, 27.1 g of potassium monoethyl malonate was added, and stirred at 25°C for 5 hours; Post-treatment: add 18% hydrochloric acid to the reaction solution to adjust the pH to below 2, continue stirring for 1 hour, separate the liquids, discard the aqueous phase, wash the obtained organic phase with 80 ml × 2 water, and concentrate and dry the organic phase under reduced pressure at 50°C to obtain 26.7 g of the intermediate compound of formula 2; 2) Preparation of intermediate compound of formula 3 Reaction: 20.0g of compound 2, 13.8g of triethyl orthoformate and 14.2g of acetic anhydride were added to the reaction flask in sequence, and the mixture was stirred at 100°C for 4 hours. After the reaction was completed, the volatile matter was evaporated under reduced pressure at the reaction temperature. When no fraction was evaporated, the mixture was cooled to 25°C in a water bath, 200ml of anhydrous ethanol was added, and 5.8g of cyclopropylamine was added dropwise. The mixture was stirred at 25°C for 5 hours. Post-treatment: The reaction solution was cooled to 5°C, 600 ml of water was added dropwise, and the mixture was stirred and crystallized at 0-10°C for 2 h, filtered, washed once with 20 ml of water, and the wet product was vacuum dried at 50°C for 12 h to obtain 24.0 g of the intermediate compound of formula 3; 3) Preparation of intermediate compound of formula 4 Reaction: 180 ml of anhydrous ethanol, 20.0 g of the compound of formula 3, 9.5 g of DIPEA and 10.1 g of potassium chloride were added to the reaction flask in sequence, and stirred at 70°C for 5 hours; Post-treatment: The reaction solution was cooled to 25°C, 600 ml of water was added dropwise, and the mixture was stirred and crystallized at 25°C for 2 h, filtered, washed once with 20 ml of anhydrous ethanol, and the wet product was vacuum dried at 60°C for 10 h to obtain 17.9 g of the intermediate compound of formula 4; 4) Preparation of the key intermediate of nemofloxacin - compound of formula 5 Reaction: Add 150 ml of water and 3.3 g of sodium hydroxide to the reaction flask in sequence, stir to dissolve completely, add 15.0 g of compound of formula 4, stir and react at 30°C for 3 hours; Post-treatment: under ice-water bath, add 18% hydrochloric acid by mass to adjust the pH to 3, maintain stirring at 20°C for crystallization for 1 hour, filter, wash once with 30 ml of water, and dry the wet product in vacuum at 60°C for 15 hours to obtain 13.1 g of nemonoxacin key intermediate.
